Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature

Nature Reviews Neurology (2020) https://doi.org/10.1038/s41582-020-0385-8 Published online 08 July 2020

In the originally published version of this article, the description of the study by Sormani et al. (ref. 14) in the third paragraph of the section entitled ‘B cell-depleting therapies’ was incorrect. The description should read:

In 232 patients with multiple sclerosis and suspected or proven COVID-19, the severity of COVID-19 was classified as mild (no or mild pneumonia) in 222 (96%), severe (shortness of breath, respiratory rate ≥30 breaths/min, blood oxygen saturation ≤93%, PaO2:FiO2 < 300 mmHg/%, and an increase in lung infiltrates of >50% within 24–48 h) in 4 (2%) and critical (respiratory failure, septic shock and multiple organ dysfunction or failure) in 6 (3%). Of the 6 patients with critical illness, 1 recovered and 5 died. Of 28 patients receiving a B cell-depleting therapy, 3 (10%) developed a severe or critical disease course14.

This description has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Heinz Wiendl.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Korsukewitz, C., Reddel, S.W., Bar-Or, A. et al. Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature. Nat Rev Neurol (2020). https://doi.org/10.1038/s41582-020-0392-9

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing